Showing results (151-160 of 206) with videos related to

Sort By:
Pageof 21
Endocrine-Related Cancer|March 30, 2018
Ki67 proliferative index of the neuroendocrine component drives MANEC prognosisMassimo Milione, Patrick Maisonneuve, Alessio Pellegrinelli, et al.
Clinical Colorectal Cancer|September 1, 2023
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal OriginFilippo Ghelardi, Alessandra Raimondi, Federica Morano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 23, 2021
A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancerGiulia Bertolini, Valeria Cancila, Massimo Milione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal CancerFilippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, et al.
JCO Precision Oncology|May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based TherapyGiovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
British Journal of Cancer|March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trialsChiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Journal of Pathology Informatics|August 23, 2017
Teaching Digital Pathology: The International School of Digital Pathology and Proposed SyllabusVincenzo Della Mea, Antonino Carbone, Carla Di Loreto, et al.
BMC Cancer|September 26, 2023
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trialFrancesca Corti, Maria Pia Brizzi, Vito Amoroso, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2016
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord OvestChiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, et al.
Scientific Reports|March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancerGiovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
Pageof 21